Marcello Vangeli

TL;DR: Long-term HA administration prolongs overall survival and might act as a disease modifying treatment in patients with decompensated cirrhosis in this trial.

TL;DR: A trend for a better patient survival was observed in more recent years but the cumulative probability of developing severe recurrent disease remained unchanged, and the combination of a female recipient receiving an older graft emerged as a strong risk factor for a severe recurrence.

TL;DR: It is concluded that combined therapy with low‐dose Ribavirin followed by long‐term ribavirin monotherapy can be recommended because it favorably modifies the natural history of recurrent hepatitis C in most patients and possibly halts histological disease progression without causing iron accumulation.

TL;DR: Sorafenib, with or without mammalian target of rapamycin inhibitors, is poorly tolerated and rarely effective in the treatment of recurrent HCC after OLT.

TL;DR: Preliminary results indicate that the KIR genotype and KIR–HLA‐C ligand compatibility play roles in the recurrence and progression of hepatitis C disease in liver transplant recipients.